Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
38results about How to "Reduce organ damage" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
InactiveUS20070154482A1Improve subject 's conditionIncrease cardiac outputCompounds screening/testingOrganic active ingredientsHigh dose therapyHigh doses
Disclosed herein are methods for treating a vascular leak disorder, hypotension, or a procoagulant state using angiopoietin-2 (Ang-2) antagonist compounds. Also disclosed are methods for treating a vascular leak disorder associated with high dose IL-2 therapy using angiopoietin-2 antagonist compounds. Methods for diagnosing and monitoring vascular leak disorders, hypotension, or a procoagulant state that include the measurement of Ang-2 polypeptide or nucleic acid levels are also disclosed. Methods for inducing a vascular leak using an Ang-2 agonist are also disclosed.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Novel Thiophene Derivatives as Sphingosine-1-Phosphate-1 Receptor Agonists
InactiveUS20080318955A1Reduction tendencyEffective activityBiocideSenses disorderAgonistThiophene derivatives
The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.
Owner:ACTELION PHARM LTD
Novel Thiophene Derivatives as Spingosine-1-Phosphate-1 Receptor Agonists
The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.
Owner:ACTELION PHARM LTD
Novel Thiophene Derivatives
InactiveUS20080300294A1Reduction tendencyEffective activityBiocideNervous disorderTerthiopheneThiophene derivatives
The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.
Owner:ACTELION PHARM LTD
Novel Pyridine Derivatives
InactiveUS20090005421A1Reduction tendencyEffective activityBiocideSenses disorderPyridineActive compound
The invention relates to novel pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.
Owner:ACTELION PHARM LTD
Novel Thiophene Derivatives
InactiveUS20080064740A1Reduction tendencyEffective activityBiocideOrganic chemistryThiophene derivativesStereochemistry
The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.
Owner:ACTELION PHARM LTD
Novel thiophene derivatives
InactiveUS20100075946A1Reduction tendencyEffective activityBiocideNervous disorderStereochemistryActive compound
The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.
Owner:ACTELION PHARM LTD
Hydrogenated Benzo (C) Thiophene Derivatives as Immunomodulators
InactiveUS20080176926A1Reduction tendencyEffective activityBiocideNervous disorderTerthiopheneThiophene derivatives
The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.
Owner:IDORSIA PHARM LTD
Pyridin-3-yl derivatives as immunomodulating agents
InactiveUS20100168005A1Reduction tendencyEffective activityBiocideSenses disorderPyridineStereochemistry
Owner:ACTELION PHARM LTD
Pyridin-4-yl derivatives as immunomodulating agents
ActiveUS20100063108A1Reduction tendencyEffective activityBiocideSenses disorderPyridineImmunomodulatory Agent
The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, R4, R5, and R6 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
Owner:IDORSIA PHARM LTD
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
InactiveUS20100221243A1Improve the situationReduce mortalityCompounds screening/testingOrganic active ingredientsHigh dosesIl-2 therapy
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Phenyl derivatives and their use as immunomodulators
InactiveUS20100087495A1Reduction tendencyEffective activityBiocideSenses disorderImmunomodulating AgentMedicinal chemistry
Owner:ACTELION PHARM LTD
Pyridine compounds
InactiveUS20110028448A1Reduction tendencyEffective activityBiocideNervous disorderPicoidesMedicinal chemistry
The invention relates to pyridine compounds, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
Owner:ACTELION PHARM LTD
Amino-pyridine derivatives as s1p1 /edg1 receptor agonists
InactiveUS20100087417A1Reduction tendencyEffective activityBiocideSenses disorderImmunomodulating AgentAgonist
The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
Owner:ACTELION PHARM LTD
Novel aminomethyl benzene derivatives
InactiveUS20110028449A1Reduction tendencyEffective activityBiocideSenses disorderImmunomodulating AgentMedicinal chemistry
The invention relates to novel aminomethyl benzene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
Owner:ACTELION PHARM LTD
Thiophene derivatives as S1P1/EDGE1 receptor agonists
InactiveUS20100048648A1Reduction tendencyEffective activityBiocideSenses disorderTerthiopheneAgonist
The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
Owner:ACTELION PHARM LTD
Thiophene derivatives
InactiveUS7750040B2Reduction tendencyEffective activityBiocideOrganic chemistryThiophene derivativesStereochemistry
Owner:ACTELION PHARM LTD
Use of L carnitine and its alkanoyl dervatives for the preparation of a medicament useful for the treatment of patients suffering from diabetic and/or dysmetabolic nephropathy
InactiveUS6696492B1Major side effectReduce organ damageBiocideUrinary disorderDiabetes mellitusMetabolism disorder
Patients suffering from diabetic and / or dysmetabolic nephropathy are treated with L-carnitine or its alkanoyl derivatives.
Owner:SIGMA TAU IND FARMACEUTICHE RIUNITE SPA
Novel pyrimidine derivatives
InactiveUS20100234346A1Reduction tendencyEffective activityOrganic active ingredientsBiocideImmunomodulating AgentCombinatorial chemistry
The invention relates to novel pyrimidine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents Formula (II), Formula (III), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII) or Formula (IX)
Owner:ACTELION PHARM LTD
Novel pyrimidine-pyridine derivatives
InactiveUS20110046170A1Reduction tendencyEffective activityOrganic active ingredientsBiocideCombinatorial chemistryActive compound
The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
Owner:ACTELION PHARM LTD
Hydrogenated benzo (C) thiophene derivatives as immunomodulators
InactiveUS7723378B2Reduction tendencyEffective activityBiocideNervous disorderStereochemistryActive compound
Owner:IDORSIA PHARM LTD
Pyridin-2-yl derivatives as immunomodulating agents
ActiveUS20100331372A1Reduction tendencyEffective activityBiocideOrganic chemistryImmunomodulating AgentPyridine
The invention relates to pyridine derivatives of Formula (I)wherein A, R1, R2, R3, R4, R5, R6 and R7 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
Owner:IDORSIA PHARM LTD
Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists
InactiveUS7605269B2Reduction tendencyEffective activityOrganic active ingredientsBiocideAgonistThiophene derivatives
Owner:ACTELION PHARM LTD
Novel thiophene derivatives as s1p1/edg1 receptor agonists
InactiveUS20100240717A1Reduction tendencyEffective activityBiocideSenses disorderAgonistThiophene derivatives
The invention relates to thiophene derivatives of formula (I) / their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents wherein: A represents *—CO—CH═CH—, *—CO—CH2CH2—, *—CO—CH2—NH—, wherein the sterisks indicate the bond that is linked to the thiophene group of Formula (I), and R1-R3 are as defined in the claims.
Owner:ACTELION PHARM LTD
Thiophene derivatives as spingosine-1-phosphate-1 receptor agonists
Owner:ACTELION PHARM LTD
Thiophene derivatives as agonists of s1p1/edg1
InactiveUS20100261702A1Reduction tendencyEffective activityBiocideNervous disorderAgonistStereochemistry
The invention relates to novel thiophene derivatives (1), their preparation and their use as pharmaceutically active compounds.Said compounds particularly act as immunomodulating agents. Formula (I).
Owner:ACTELION PHARM LTD
Pyridine derivatives as s1p1/edg1 receptor modulators
InactiveUS20110212998A1Reduction tendencyEffective activityBiocideSenses disorderImmunomodulating AgentPyridine
The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims.
Owner:ACTELION PHARM LTD
Pyridine derivatives
InactiveUS8178562B2Reduction tendencyEffective activityBiocideSenses disorderPyridineActive compound
The invention relates to novel pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.
Owner:ACTELION PHARM LTD
Thiophene derivatives
InactiveUS7951794B2Reduction tendencyEffective activityBiocideNervous disorderThiophene derivativesPerylene derivatives
The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.
Owner:ACTELION PHARM LTD
Thiophene derivatives
InactiveUS7981924B2Reduction tendencyEffective activityBiocideNervous disorderThiophene derivativesPerylene derivatives
The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.
Owner:ACTELION PHARM LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com